Early detection of malignant and pre-malignant peripheral nerve tumors using cell-free DNA fragmentomics

R. Taylor Sundby,Jeffrey J. Szymanski,Alexander Pan,Paul A. Jones,Sana Z. Mahmood,Olivia H. Reid,Divya Srihari,Amy E Armstrong,Stacey Chamberlain,Sanita Burgic,Kara Weekley,Béga Murray,Sneh Patel,Faridi Qaium,Andrea N. Lucas,Margaret Fagan,Anne Dufek,Christian F. Meyer,Natalie B. Collins,Christine A. Pratilas,Eva Dombi,Andrea M. Gross,AeRang Kim,John S.A. Chrisinger,Carina A. Dehner,Brigitte C. Widemann,Angela C. Hirbe,Aadel A. Chaudhuri,Jack F. Shern
DOI: https://doi.org/10.1101/2024.01.18.24301053
2024-03-11
Abstract:Early detection of neurofibromatosis type 1 (NF1) associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, potentially averting deadly outcomes. Here, we describe a cell-free DNA (cfDNA) fragmentomic approach which distinguishes non-malignant, pre-malignant and malignant forms of NF1 PNST. Using plasma samples from a novel cohort of 101 NF1 patients and 21 healthy controls, we validated that our previous cfDNA copy number alteration (CNA)-based approach identifies malignant peripheral nerve sheath tumor (MPNST) but cannot distinguish among benign and premalignant states. We therefore investigated the ability of fragment-based cfDNA features to differentiate NF1-associated tumors including binned genome-wide fragment length ratios, end motif analysis, and non-negative matrix factorization deconvolution of fragment lengths. Fragmentomic methods were able to differentiate pre-malignant states including atypical neurofibromas (AN). Fragmentomics also adjudicated AN cases suspicious for MPNST, correctly diagnosing samples noninvasively, which could have informed clinical management. Overall, this study pioneers the early detection of malignant and premalignant peripheral nerve sheath tumors in NF1 patients using plasma cfDNA fragmentomics. In addition to screening applications, this novel approach distinguishes atypical neurofibromas from benign plexiform neurofibromas and malignant peripheral nerve sheath tumors, enabling more precise clinical diagnosis and management.
Genetic and Genomic Medicine
What problem does this paper attempt to address?